# US 2021/0010092 A1 · Gene relevant to papillary thyroid tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0010092 A1
- Document ID: US20210010092A1
- Status: Published application
- Kind: A1
- Application number: 17/032,414
- Filed: 2020-09-25
- Published: 2021-01-14
- Earliest claimed: 2015-05-13
- Assignees: Bozhou Xinjiankang Science and Technology Co., Ltd
- Applicants: Bozhou Xinjiankang Science and Technology Co., Ltd
- Inventors: LIANGZHONG XIONG
- Web page: https://patentgrep.com/patent/US20210010092A1

## CPC

- A61P 35/00: Antineoplastic agents
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- C12Q 2600/158: Expression markers
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to a gene relevant to papillary thyroid tumors and an application thereof. According to the base sequence of the gene, real-time and quantitative PCR (Polymerase Chain Reaction) primers are designed and synthesized; the expression level of long-chain non-coding RNA (Ribonucleic Acid) transcribed by the gene is detected in a papillary thyroid carcinoma clinical case specimen; the result shows remarkable reducing of the expression level of the long-chain non-coding RNA in papillary thyroid tumor tissues and the long-chain non-coding RNA of the gene silencing can remarkably promote the growth of thyroid cancer cells. The gene relevant to the papillary thyroid tumors is expected to prepare preparations used in papillary thyroid carcinoma auxiliary diagnosis, gene therapy, curative effect prediction or prognosis.

## Claims

### Claim 1

A method of detecting a long non-coding GAS8-AS1 gene or mRNA in a subject, the method comprising:
obtaining a sample from the subject;
mixing the sample with a forward primer and a reverse primer, the reverse primer including a sequence of CAACGAGCAAACAAGAAGGAG as represented by SEQ ID NO:2 or TGAGCCAAACAGACCAGTCA as represented by SEQ ID NO:3, the sequence is labeled with a FAM fluorescence label; and
amplifying and detecting the long non-coding GAS8-AS1 gene at positions 240-427, located in the intron 2 of human chromosome 16.

### Claim 2 (depends on 1)

The method of detecting a long non-coding GAS8-AS1 gene or mRNA in a subject according to claim 1, wherein:
the sample is thyroid carcinoma tissues of the subject.

### Claim 3 (depends on 1)

The method of detecting a long non-coding GAS8-AS1 gene or mRNA in a subject according to claim 1, wherein:
the sample is peripheral blood of the subject.

### Claim 4

A method of diagnosing papillary thyroid carcinoma, the method comprising:
obtaining a sample of papillary thyroid cells from a patient;
hybridizing a nucleic acid molecule having a sequence of
FAM-GGATCCCAACGAGCAAACAAGAAGGAG as represented by
SEQ ID NO: 2
or
GGATCCTGAGCCAAACAGACCAGTCA as represented by SEQ ID
NO: 3
with a long non-coding GAS8-AS1 gene represented by SEQ ID NO:1 in the sample under stringent conditions; and,
diagnosing a patient as having or at an increased risk of developing papillary thyroid carcinoma when expression levels of the gene represented by SEQ ID NO:1 in the sample are at least 40% lower as compared to the expression levels of the gene represented by SEQ ID NO:1 in a healthy person.

### Claim 5 (depends on 4)

The method of diagnosing papillary thyroid carcinoma according to claim 4, wherein:
the sample is thyroid carcinoma tissues of the patient.

### Claim 6 (depends on 4)

The method of diagnosing papillary thyroid carcinoma according to claim 4, wherein:
the sample is peripheral blood of the patient.

### Claim 7

A method of treating a subject diagnosed as having papillary thyroid carcinoma, the method comprising:
administering the subject an therapeutic agent comprising a nucleic acid sequence having a long non-coding GAS8-AS1 gene represented by SEQ ID NO:1.
